A071702 A Phase II Study Of Checkpoint Blockade Immunotherapy In Patients With Somatically Hypermutated Recurrent Glioblastoma
Posted Date: May 24, 2021
- Investigator: Soma Sengupta
- Specialties: Cancer, Neurology, Oncology
- Type of Study: Drug
The primary objective of this study is to determine whether the combination of ipilimumab and nivolumab increases the tumor response rate assessed by modified Response Assessment in Neuro-Oncology (RANO) Criteria in patients with hypermutated recurrent glioblastoma. Efficacy will be determined by measuring overall response rate.
Criteria:
Histologically Confirmed Glioblastoma, Presence Of Measurable Disease Prior To Resection Or Biopsy Of Recurrent Tumor, Ecog Score Of 0-2, No Active Autoimmune Disease Or History Of Autoimmune Disease, No Prior Treatment With Checkpoint Blockade Therapies (Anti-Ctla4, Anti-Pd1/Pd-L1) Or Bevacizumab
Keywords:
Glioblastoma, Brain, Neuro-Oncology
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com